title: Transcatheter aortic valve replacement with the Portico valve: one-year results of the early Canadian experience.
abstract: OBJECTIVE
  The aim of this study was to examine the short- and medium-term outcomes of transcatheter aortic valve replacement (TAVR) with the self-expanding and repositionable Portico valve (St. Jude Medical, St. Paul, MN, USA).
  
  
  RESULTS
  A total of 57 patients underwent TAVR with the Portico valve between March 2012 and August 2014, representing the first-in-human experience and the entire early experience in Canada. Patients were followed up at 30 days and one year with repeat echocardiography and clinical review. Patients were 80.8±7.3 years of age, and the Society of Thoracic Surgeons predicted risk of mortality was 7.7±5.7%. All patients had a valve implanted and four patients (7%) required a second valve. At 30 days, there were two deaths (3.5%), three disabling strokes (5.3%), and new pacemakers in five (8.8%) patients. Echocardiography revealed moderate/severe aortic regurgitation in two patients (3.6%). At one year, survival was 84.2% and echocardiographic findings were unchanged.
  
  
  CONCLUSIONS
  Transcatheter aortic valve replacement with the repositionable Portico valve provides satisfactory short- and medium-term haemodynamic and clinical results.
authors.affiliation: St. Paul's Hospital, Vancouver, British Columbia, Canada.
authors.forename: Gidon Y
authors.initials: GY
authors.lastname: Perlman
authors.forename: Anson
authors.initials: A
authors.lastname: Cheung
authors.forename: Eric
authors.initials: E
authors.lastname: Dumont
authors.forename: Dion
authors.initials: D
authors.lastname: Stub
authors.forename: Danny
authors.initials: D
authors.lastname: Dvir
authors.forename: Maria
authors.initials: M
authors.lastname: Del Trigo
authors.forename: Marc
authors.initials: M
authors.lastname: Pelletier
authors.forename: Sami
authors.initials: S
authors.lastname: Alnasser
authors.forename: Jian
authors.initials: J
authors.lastname: Ye
authors.forename: David
authors.initials: D
authors.lastname: Wood
authors.forename: Christopher
authors.initials: C
authors.lastname: Thompson
authors.forename: Philipp
authors.initials: P
authors.lastname: Blanke
authors.forename: Jonathon
authors.initials: J
authors.lastname: Leipsic
authors.forename: Michael A
authors.initials: MA
authors.lastname: Seidman
authors.forename: Heather
authors.initials: H
authors.lastname: LeBlanc
authors.forename: Christopher E
authors.initials: CE
authors.lastname: Buller
authors.forename: Josep
authors.initials: J
authors.lastname: Rodés-Cabau
authors.forename: John G
authors.initials: JG
authors.lastname: Webb
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve / Q000601:surgery*; D001022:Aortic Valve Insufficiency / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000601:surgery*; D002170:Canada; D006328:Cardiac Catheterization / Q000379:methods; D005260:Female; D019918:Heart Valve Prosthesis Implantation / Q000379:methods; D006801:Humans; D008297:Male; D012307:Risk Factors; D065467:Transcatheter Aortic Valve Replacement / Q000379:methods; D016896:Treatment Outcome